Clinical Trial: A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
Study Status: Completed
Recruit Status: RECRUITING
Condition: Metastatic Urothelial Carcinoma
Study Type: INTERVENTIONAL
Official Title: A Phase 1/2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab Plus Enfortumab Vedotin (EV) in Combination With Investigational Agents Versus Pembrolizumab Plus EV, a
Brief Summary:
This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04.The substudy will consist of 2 parts.Part 1 will evaluate the efficacy and safety of coformulated favezelimab/pembrolizumab plus EV and coformulated vibostolimab/pembrolizumab plus EV relative to pembrolizumab plus EV.There will be no comparison of coformulated favezelimab/pembrolizumab plus EV versus coformulated vibostolimab/pembrolizumab plus EV.If ORR and/or DRR are substantially better…
Read more